X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1505) 1505
Publication (126) 126
Book Review (23) 23
Magazine Article (7) 7
Book Chapter (2) 2
Conference Proceeding (2) 2
Book / eBook (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1316) 1316
male (881) 881
indans - therapeutic use (878) 878
female (744) 744
indans - adverse effects (693) 693
index medicus (677) 677
aged (669) 669
piperidines - therapeutic use (602) 602
donepezil (527) 527
alzheimer disease - drug therapy (486) 486
middle aged (465) 465
cholinesterase inhibitors - therapeutic use (449) 449
piperidines - adverse effects (423) 423
treatment outcome (399) 399
indans - administration & dosage (395) 395
pharmacology & pharmacy (372) 372
double-blind (341) 341
alzheimer's disease (334) 334
cholinesterase inhibitors - adverse effects (323) 323
indans - pharmacology (323) 323
clinical neurology (292) 292
animals (285) 285
dementia (281) 281
double-blind method (280) 280
aged, 80 and over (275) 275
psychiatry (267) 267
adult (264) 264
alzheimers-disease (234) 234
efficacy (229) 229
nootropic agents - therapeutic use (227) 227
rivastigmine (203) 203
dose-response relationship, drug (198) 198
drug therapy (194) 194
neurosciences (191) 191
geriatrics & gerontology (184) 184
piperidines - administration & dosage (182) 182
safety (171) 171
nootropic agents - adverse effects (159) 159
rats (150) 150
piperidines - pharmacology (146) 146
pulmonary disease, chronic obstructive - drug therapy (144) 144
severity of illness index (144) 144
indans - pharmacokinetics (143) 143
cholinesterase inhibitors (140) 140
drug therapy, combination (140) 140
placebo-controlled trial (140) 140
parkinson disease - drug therapy (138) 138
cholinesterase inhibitors - administration & dosage (137) 137
neuropsychological tests (134) 134
cholinesterase inhibitors - pharmacology (130) 130
time factors (127) 127
galantamine - therapeutic use (117) 117
alzheimer disease - psychology (113) 113
quinolones - administration & dosage (112) 112
randomized controlled trials as topic (110) 110
care and treatment (109) 109
parkinson's disease (109) 109
indacaterol (108) 108
drug administration schedule (107) 107
medicine, general & internal (105) 105
analysis (104) 104
research (101) 101
cognition - drug effects (100) 100
alzheimers disease (99) 99
gerontology (98) 98
cholinesterase-inhibitors (95) 95
quinolones - adverse effects (95) 95
respiratory system (94) 94
cognition disorders - drug therapy (93) 93
rasagiline (93) 93
phenylcarbamates - therapeutic use (92) 92
quinolones - therapeutic use (91) 91
galantamine (88) 88
clinical trials (87) 87
clinical trials as topic (87) 87
cognition (86) 86
dementia - drug therapy (85) 85
drug interactions (85) 85
bronchodilator agents - administration & dosage (84) 84
dosage and administration (82) 82
pulmonary disease, chronic obstructive - physiopathology (80) 80
therapy (80) 80
lung diseases, obstructive (78) 78
memantine - therapeutic use (78) 78
copd (76) 76
galantamine - adverse effects (74) 74
tiotropium (73) 73
memantine (72) 72
trial (72) 72
piperidines - pharmacokinetics (71) 71
bronchodilator agents - therapeutic use (70) 70
administration, oral (69) 69
bronchodilator agents - adverse effects (69) 69
mice (69) 69
moderate (68) 68
neuroprotective agents - therapeutic use (68) 68
chronic obstructive pulmonary disease (65) 65
cross-over studies (65) 65
obstructive pulmonary-disease (65) 65
adolescent (64) 64
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1443) 1443
German (16) 16
Spanish (14) 14
Japanese (13) 13
French (12) 12
Danish (4) 4
Chinese (3) 3
Hungarian (2) 2
Dutch (1) 1
Finnish (1) 1
Italian (1) 1
Norwegian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Psychopharmacology, ISSN 0033-3158, 6/2015, Volume 232, Issue 11, pp. 1859 - 1866
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 3 - 14
Marine sponges have consistently been the richest source of new marine natural products with unprecedented chemical scaffolds and potent biological activities... 
Porifera | Marine natural products | Drug discovery | ANDROGEN RECEPTOR | INOSITOL 5-PHOSPHATASE | MAST-CELLS | PAPUA-NEW-GUINEA | STRUCTURE ELUCIDATION | MARINE SPONGE | SHIP1 ACTIVATOR AQX-1125 | IN-VIVO | PHARMACOLOGY & PHARMACY | CYSTITIS/BLADDER PAIN SYNDROME | RESISTANT PROSTATE-CANCER | Indans - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Drugs, Investigational - therapeutic use | Antineoplastic Agents - therapeutic use | Prodrugs - chemistry | Nonsteroidal Anti-Androgens - chemistry | Oligopeptides - therapeutic use | Nonsteroidal Anti-Androgens - therapeutic use | Sterols - adverse effects | Glycerol - analogs & derivatives | Porifera - chemistry | Benzhydryl Compounds - therapeutic use | Oligopeptides - chemistry | Anti-Asthmatic Agents - chemistry | Glycerol - therapeutic use | Indans - chemistry | Anti-Asthmatic Agents - pharmacology | Pyrrolidinones - adverse effects | Antimitotic Agents - adverse effects | Pyrrolidinones - therapeutic use | Antimitotic Agents - therapeutic use | Biological Products - isolation & purification | Biological Products - chemistry | Pyrrolidinones - isolation & purification | Cyclohexanols - therapeutic use | Oligopeptides - pharmacology | Anti-Asthmatic Agents - adverse effects | Cyclohexanols - adverse effects | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Oligopeptides - adverse effects | Indans - therapeutic use | Benzhydryl Compounds - chemistry | Drugs, Investigational - chemistry | Sterols - therapeutic use | Benzhydryl Compounds - adverse effects | Antineoplastic Agents - adverse effects | Cyclohexanols - chemistry | Nonsteroidal Anti-Androgens - adverse effects | Drug Design | Antineoplastic Agents - pharmacology | Glycerol - pharmacology | Aquatic Organisms - chemistry | Nonsteroidal Anti-Androgens - pharmacology | Sterols - pharmacology | Sterols - chemistry | Antineoplastic Agents - chemistry | Drug Discovery | Pyrrolidinones - chemistry | Prodrugs - adverse effects | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antimitotic Agents - pharmacology | Benzhydryl Compounds - pharmacology | Prodrugs - therapeutic use | Prodrugs - pharmacology | Antimitotic Agents - chemistry | Chemical oceanography | Index Medicus
Journal Article
Clinical Neuropharmacology, ISSN 0362-5664, 2014, Volume 37, Issue 2, pp. 62 - 62
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 10, pp. 893 - 903
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article